ClinicalTrials.gov

History of Changes for Study: NCT02735707
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (REMAP-CAP)
Latest version (submitted October 8, 2020) on ClinicalTrials.gov
  • A study version is represented by a row in the table.
  • Select two study versions to compare. One each from columns A and B.
  • Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
  • Click "Compare" to do the comparison and show the differences.
  • Select a version's Submitted Date link to see a rendering of the study for that version.
  • The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
  • Hover over the "Recruitment Status" to see how the study's recruitment status changed.
  • Study edits or deletions are displayed in red.
  • Study additions are displayed in green.
Study Record Versions
Version A B Submitted Date Changes
1 April 6, 2016 None (earliest Version on record)
2 October 26, 2016 Study Status
3 March 10, 2017 Study Identification, Study Status and Study Description
4 August 16, 2018 Contacts/Locations, Arms and Interventions, Outcome Measures, Study Status, Sponsor/Collaborators, References, Study Identification, Study Description, Oversight, Eligibility, Study Design and Conditions
5 January 9, 2019 Contacts/Locations and Study Status
6 March 25, 2020 Arms and Interventions, Contacts/Locations, Outcome Measures, Conditions, Study Description, Study Status, References, Eligibility, Sponsor/Collaborators and Study Identification
7 April 15, 2020 Arms and Interventions, Contacts/Locations, Study Status, Outcome Measures, References, Eligibility, Study Design, Conditions, Study Description and Sponsor/Collaborators
8 July 17, 2020 Arms and Interventions, Study Description, Study Status, References, Contacts/Locations, Eligibility, Outcome Measures and Conditions
9 October 8, 2020 Arms and Interventions, Oversight and Study Status
Comparison Format:

Scroll up to access the controls

Changes (Side-by-Side) for Study: NCT02735707
March 25, 2020 (v6) -- April 15, 2020 (v7)

Changes in: Arms and Interventions, Contacts/Locations, Study Status, Outcome Measures, References, Eligibility, Study Design, Conditions, Study Description and Sponsor/Collaborators

Study Identification
Unique Protocol ID: U1111-1189-1653 U1111-1189-1653
Brief Title: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (REMAP-CAP)Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (REMAP-CAP)
Official Title: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Secondary IDs: 2015-002340-14 [EudraCT Number]
602525 [Other Grant/Funding Number: European Union, FP7-HEALTH-2013-INNOVATION-1, PREPARE]
16/631 [Other Grant/Funding Number: Platform Trial Optimising Interventions in Severe Community Acquired Pneumonia Health Research Council, New Zealand)]
APP1101719 [Other Grant/Funding Number: OPTIMISE-CAP, The National Health and Medical Research Council, Australia]
158584 [Other Grant/Funding Number: Canadian Institute of Health Research, Strategy for Patient-Oriented Research (CIHR-]
2015-002340-14 [EudraCT Number]
602525 [Other Grant/Funding Number: European Union, FP7-HEALTH-2013-INNOVATION-1, PREPARE]
16/631 [Other Grant/Funding Number: Platform Trial Optimising Interventions in Severe Community Acquired Pneumonia Health Research Council, New Zealand)]
APP1101719 [Other Grant/Funding Number: OPTIMISE-CAP, The National Health and Medical Research Council, Australia]
158584 [Other Grant/Funding Number: Canadian Institute of Health Research, Strategy for Patient-Oriented Research (CIHR-]
Study Status
Record Verification: March 2020 April 2020
Overall Status: Recruiting Recruiting
Study Start: April 11, 2016 April 11, 2016
Primary Completion: December 2021 [Anticipated ] December 2021 [Anticipated ]
Study Completion: June 2022 [Anticipated ] December 2023 [Anticipated ]
First Submitted: December 11, 2015 December 11, 2015
First Submitted that
Met QC Criteria:
April 6, 2016 April 6, 2016
First Posted: April 13, 2016 [Estimate ] April 13, 2016 [Estimate ]
Last Update Submitted that
Met QC Criteria:
March 25, 2020 April 15, 2020
Last Update Posted: March 30, 2020 [Actual ] April 16, 2020 [Actual ]
Sponsor/Collaborators
Sponsor: MJM Bonten MJM Bonten
Responsible Party: Sponsor-Investigator
Investigator: MJM Bonten
Official Title: Prof. Medical Microbiology
Affiliation: UMC Utrecht
Sponsor-Investigator
Investigator: MJM Bonten
Official Title: Prof. Medical Microbiology
Affiliation: UMC Utrecht
Collaborators: Australian and New Zealand Intensive Care Research Centre
Medical Research Institute of New Zealand
Unity Health
Berry Consultants
Australian and New Zealand Intensive Care Research Centre
Medical Research Institute of New Zealand
Unity Health
Berry Consultants
Global Coalition for Adaptive Research
University of Pittsburgh Medical Center
Oversight
U.S. FDA-regulated Drug: No No
U.S. FDA-regulated Device: No No
Data Monitoring: Yes Yes
Study Description
Brief Summary:

REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia.

The purpose of this study is to evaluate the effect of a range of interventions to improve outcome ofon patients admitted to intensive care with community-acquired pneumonia.

In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic resulting in critical illness.

REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia.

The purpose of this study is to evaluate the effect of a range of interventions to improve outcome ofon patients admitted to intensive care with community-acquired pneumonia.

In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic resulting in critical illness.

REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19.

Detailed Description:

Community-acquired pneumonia (CAP) that is of sufficient severity to require admission to an intensive care unit (ICU) is associated with substantial mortality.

Patients with pneumonia who are being treated in an ICU will receive therapy that consists of many different treatments, as many as 20 or 30. These treatments act together to treat both the infection and its effects on the body. When treating a patient, doctors choose from many different treatments, most of which are known or believed to be safe and effective. However, doctors don't always know which treatment option is the better one, as individuals or groups of individuals may respond differently. This study aims to help doctors understand which treatments work best.

This clinical study has been designed in a way that allows the information from patients already in the study to help new patients joining the study. Most studies aren't able to do that. REMAP-CAP has been designed to:

  • Evaluate multiple treatment strategies, at the same time, in the same patient.
  • Reach platform conclusions when sufficient data is accrued, rather than when a pre-specified sample size is reached
  • Utilise data that is already accrued to increase the likelihood that patients within the trial are randomised to treatments that are more likely to be beneficial
  • New questions can be substituted into the trial as initial questions are answered, meaning that the trial can be perpetual or open-ended
  • Interactions between interventions in different domains can be evaluated

Community-acquired pneumonia (CAP) that is of sufficient severity to require admission to an intensive care unit (ICU) is associated with substantial mortality.

Patients with pneumonia who are being treated in an ICU will receive therapy that consists of many different treatments, as many as 20 or 30. These treatments act together to treat both the infection and its effects on the body. When treating a patient, doctors choose from many different treatments, most of which are known or believed to be safe and effective. However, doctors don't always know which treatment option is the better one, as individuals or groups of individuals may respond differently. This study aims to help doctors understand which treatments work best.

This clinical study has been designed in a way that allows the information from patients already in the study to help new patients joining the study. Most studies aren't able to do that. REMAP-CAP has been designed to:

  • Evaluate multiple treatment strategies, at the same time, in the same patient.
  • Reach platform conclusions when sufficient data is accrued, rather than when a pre-specified sample size is reached
  • Utilise data that is already accrued to increase the likelihood that patients within the trial are randomised to treatments that are more likely to be beneficial
  • New questions can be substituted into the trial as initial questions are answered, meaning that the trial can be perpetual or open-ended
  • Interactions between interventions in different domains can be evaluated
Conditions
Conditions: Community-acquired Pneumonia, Influenza, COVID-19 Community-acquired Pneumonia, Influenza, COVID-19
Keywords: Pneumonia
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Anti-Bacterial Agents
Moxifloxacin
Levofloxacin
Antibiotics
Hydrocortisone
Anti-Infective Agents
Ceftriaxone
Piperacillin-tazobactam
Ceftaroline
Amoxicillin-clavulanate
Oseltamivir
COVID-19
Influenza
Intensive care
Critical care
Pneumonia
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Anti-Bacterial Agents
Moxifloxacin
Levofloxacin
Antibiotics
Hydrocortisone
Anti-Infective Agents
Ceftriaxone
Piperacillin-tazobactam
Ceftaroline
Amoxicillin-clavulanate
Oseltamivir
COVID-19
Influenza
Intensive care
Critical care
SARS-CoV-2
Study Design
Study Type: InterventionalInterventional
Primary Purpose: TreatmentTreatment
Study Phase: Phase 4Phase 4
Interventional Study Model: Factorial Assignment Factorial Assignment
Number of Arms: 2023
Masking: None (Open Label)None (Open Label)
Allocation: RandomizedRandomized
Enrollment: 6800 [Anticipated ] 7100 [Anticipated ]
Arms and Interventions
Arms Assigned Interventions
Active Comparator: Corticosteroid Domain: fixed-duration Hydrocortisone
The patient will receive IV Hydrocortisone 50 mg every 6 hours for up to 7 days.
Drug: Fixed-duration Hydrocortisone
50mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days.
No Intervention: Corticosteroid Domain:No systemic corticosteroid (no placebo)
The patient will receive no systemic corticosteroid for the treatment of CAP or its direct complications, up until study day 28.
Active Comparator: Corticosteroid Domain: shock dependant Hydrocortisone
The patient will receive hydrocortisone (50mg IV every 6 hours) while the patient is in septic shock.
Drug: Shock-dependent hydrocortisone
Patient will receive 50mg IV hydrocortisone every 6 hours while the patient is in septic shock
Active Comparator: Antibiotic Domain: Ceftriaxone + Macrolide
Ceftriaxone and site preferred macrolide will be administered for empiric antibiotic therapy
Drug: Ceftriaxone
The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
Active Comparator: Antibiotic Domain: Moxifloxacin or Levofloxacin
Moxifloxacin or levofloxacin will be administered for empiric antibiotic therapy
Drug: Moxifloxacin or Levofloxacin
The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
Active Comparator: Antibiotic Domain: Piperacillin-tazobactam + Macrolide
Piperacillin-tazobactam and site preferred macrolide will be administered for empiric antibiotic therapy
Drug: Piperacillin-tazobactam
The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
Active Comparator: Antibiotic Domain: Ceftaroline + Macrolide
Ceftaroline and site preferred macrolide will be administered for empiric antibiotic therapy
Drug: Ceftaroline

The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.

Ceftaroline is not available at commencement

Active Comparator: Antibiotic Domain: Amoxicillin-clavulanate + Macrolide
Amoxicillin-clavunate and site preferred macrolide will be administered for empiric antibiotic therapy
Drug: Amoxicillin-clavulanate
The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
Active Comparator: Macrolide Duration Domain: Standard course macrolide
The patient will receive macrolide therapy for 3-5 days. This arm is nested within the Antibiotic Domain.
Drug: Macrolide administered for 3-5 days

Standard course of macrolide therapy, discontinued between study day 3 and the end of study day 5.

The dosing of and route of administration is not protocolised, the following guidance is provided:

  • Initial IV administration of a macrolide is strongly preferred
  • The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted.
  • The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted.
Other Names:
  • Standard course macrolide
Active Comparator: Macrolide Duration Domain: Extended course macrolide
The patient will receive macrolide therapy for up to 14 days. This arm is nested within the Antibiotic Domain.
Drug: Macrolide administered for up to 14 days

Extended course of macrolide therapy discontinued at the end of study day 14 or hospital discharge (whichever occurs first).

The dosing of and route of administration is not protocolised, the following guidance is provided:

  • Initial IV administration of a macrolide is strongly preferred
  • The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted.
  • The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted.
Other Names:
  • Extended course macrolide
No Intervention: No antiviral agent active against influenza (no placebo)
The patient will receive no antiviral agent active against influenza, including oseltamivir.
Active Comparator: Five-day course of Oseltamivir
The patient will receive a five-day course of oseltamivir.
Drug: Five-days oseltamivir
Oseltamivir administered enterally twice daily for 5 days or until hospital discharge (whichever occurs first)
Active Comparator: 10-day course of oseltamivir
The patient will receive a ten-day course of oseltamivir.
Drug: Ten-days oseltamivir
Oseltamivir administered enterally twice daily for 10 days or until hospital discharge (whichever occurs first)
No Intervention: No antiviral for COVID-19
The patient will receive no antiviral agent intended to be active against SARS-CoV-2 infection.
Active Comparator: Lopinavir/ritonavir for COVID-19
Patients will receive lopinavir/ritonavir (kaletra) 400/100mg enterally every 12 hours intended to be active against SARS-CoV-2 infection.
Drug: Lopinavir/ritonavir
Lopinavir/ritonavir 400/100mg administered enterally, or 5ml 80/20mg per mL solution suspension via gastric tube, every 12 hours. Administered for a minimum of 5 days, including if discharged from ICU prior to end of study day 5. For patients discharged from ICU between study day 6 and study day 14, lopinavir/ritonavir is ceased at ICU discharge. Lopinavir/ritonavir is ceased at the end of study day 14 if the patient remains in ICU.
Other Names:
  • Kaletra
Active Comparator: Hydroxychloroquine for COVID-19
Patients will receive hydroxychloroquine intended to be active against SARS-CoV-2 infection.
Drug: Hydroxychloroquine
Loading dose of 400 800mg hydroxychloroquine administered enterally every 8 6 hours until 9 2 doses have been administered. Subsequently, 200 400mg hydroxychloroquine will be administered enterally every 12 hours until for 12 doses or ICU discharge of end of study day 10 (whichever occurs first).
Active Comparator: Hydroxychloroquine + lopinavir/ritonavir for COVID-19
Patients will receive both hydroxychloroquine and lopinavir/ritonavir intended to be active against SARS-CoV-2 infection.
Drug: Hydroxychloroquine + lopinavir/ritonavir

Lopinavir/ritonavir 400/100mg administered enterally, or 5ml 80/20mg per mL solution suspension via gastric tube, every 12 hours. Administered for a minimum of 5 days, including if discharged from ICU prior to end of study day 5. For patients discharged from ICU between study day 6 and study day 14, lopinavir/ritonavir is ceased at ICU discharge. Lopinavir/ritonavir is ceased at the end of study day 14 if the patient remains in ICU.

Loading dose of 400 800mg hydroxychloroquine administered enterally every 8 6 hours until 9 2 doses have been administered. Subsequently, 200 400mg hydroxychloroquine will be administered enterally every 12 hours until for 12 doses or ICU discharge of end of study day 10 (whichever occurs first).

No Intervention: No immune modulation for COVID-19
Patients will not receive any immune modulating therapy intended to be active against COVID-19.
Active Comparator: Interferon-β1a for COVID-19
Patients will receive Interferon-β1a daily for six days or until ICU discharge intended to be active against SARS-CoV-2 infection. COVID-19.
Drug: Interferon-β1a
IFN-β1a 10 μg will be diluted in 1 mL of sterile water. The diluted IFN-β1a will be administered as an intravenous bolus injection via a central or peripheral line. The injection will be followed with a 5 mL flush of sterile saline. IFN-β1a will be administered once daily for 6 days or until ICU discharge, whichever occurs first.
Other Names:
  • IFN-β1a
Active Comparator: Anakinra (interleukin-1 receptor antagonist) for COVID-19
Patients will receive anakinra 300mg daily intended to be active against SARS-CoV-2 infection. COVID-19.
Drug: Anakinra

A loading dose of 300mg anakinra will be administered as a bolus via central or peripheral line once daily . This is followed by maintenance doses of 100mg of anakinra administered very 6 hours.

In patients with renal impairment, anakinra will be administered on alternate days.

Other Names:
  • Interleukin-1 receptor antagonist (IL-1Ra)
Active Comparator: Fixed-duration higher dose Hydrocortisone
The patient will receive IV Hydrocortisone 100mg every 6 hours for up to 7 days.
Drug: Fixed-duration higher dose Hydrocortisone
100mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days.
Active Comparator: Tocilizumab
Patients will receive Tocilizumab intended to be active against COVID-19
Drug: Tocilizumab

Tocilizumab will be administered as a single dose of 8mg/kg estimated or measured body weight, with a maximum total dose of 800mg.

Tocilizumab will be administered as an IV infusion via central or peripheral line over a one-hour period.

Active Comparator: Sarilumab
Patients will receive Sarilumab intended to be active against COVID-19
Drug: Sarilumab
Sarilumab will be administered as a single dose of 400mg, via IV infusion through peripheral or central line over a one-hour period.
Outcome Measures
Primary Outcome Measures:
1. All-cause mortality
Day 90
All-cause mortality
Day 90
2. Days alive and outside of ICU
Primary end-point for patients with suspected or proven pandemic infection

[Time Frame: Day 21 ]
Days alive and outside of ICU
Primary end-point for patients with suspected or proven COVID-19 pandemic infection

[Time Frame: Day 21 ]
Secondary Outcome Measures:
3. ICU Mortality
Day 90
ICU Mortality
Day 90
4. ICU length of stay
Day 90
ICU length of stay
Day 90
5. Hospital length of stay
Day 90
Hospital length of stay
Day 90
6. Ventilator free days
Day 28
Ventilator free days
Day 28
7. Organ failure free days
Day 28
Organ failure free days
Day 28
8. All-cause mortality
6 months
All-cause mortality
6 months
9. Health-related Quality of life assessment
EQ5D-5L and WHODAS 2.0 (not completed in all regions)

[Time Frame: 6 months ]
Health-related Quality of life assessment
EQ5D-5L and WHODAS 2.0 (not completed in all regions)

[Time Frame: 6 months ]
10. Proportion of intubated patients who receive a tracheostomy
Day 28
Proportion of intubated patients who receive a tracheostomy
Day 28
11. Destination at time of hospital discharge
Characterised as home, rehabilitation hospital, nursing home or long-term care facility, or another acute hospital

[Time Frame: Free text Day 90 ]
Destination at time of hospital discharge
Characterised as home, rehabilitation hospital, nursing home or long-term care facility, or another acute hospital

[Time Frame: Free text Day 90 ]
12. Readmission to the index ICU during the index hospitalization
Day 90
Readmission to the index ICU during the index hospitalization
Day 90
13. World Health Organisation 8-point ordinal scale outcome
Hospital discharge
Other Pre-specified Outcome Measures:
14. Occurrence of multi-resistant organism colonisation/infection
Antibiotic Domain specific outcome

[Time Frame: Day 90, censored at hospital discharge ]
Occurrence of multi-resistant organism colonisation/infection
Antibiotic Domain specific outcome

[Time Frame: Day 90, censored at hospital discharge ]
15. Occurrence clostridium difficile
Antibiotic Domain specific outcome

[Time Frame: Day 90, censored at hospital discharge ]
Occurrence clostridium difficile
Antibiotic Domain specific outcome

[Time Frame: Day 90, censored at hospital discharge ]
16. Occurrence of serious ventricular arrhythmia (including ventricular fibrillation) or sudden unexpected death
Macrolide Duration domain specific outcome, and COVID-19 Antiviral Domain specific outcome.

[Time Frame: Day 90, censored at hospital discharge ]
Occurrence of serious ventricular arrhythmia (including ventricular fibrillation) or sudden unexpected death
Macrolide Duration domain specific outcome, and COVID-19 Antiviral Domain specific outcome.

[Time Frame: Day 90, censored at hospital discharge ]
17. Change from baseline influenza virus levels in upper and lower respiratory tract specimens
Antiviral Domain specific outcome. Only required at selected sites.

[Time Frame: Day 3, up to Day 7 ]
Change from baseline influenza virus levels in upper and lower respiratory tract specimens
Antiviral Domain specific outcome. Only required at selected sites.

[Time Frame: Day 3, up to Day 7 ]
18. Serial detection of SARS-CoV-2 in upper or lower respiratory tract specimens (using only specimens collected for routine clinical testing)
COVID-19 Antiviral Domain and COVID-19 Immune Modulation Domain specific endpoint

[Time Frame: Day 90, censored at hospital discharge ]
Serial detection of SARS-CoV-2 in upper or lower respiratory tract specimens (using only specimens collected for routine clinical testing)
COVID-19 Antiviral Domain and COVID-19 Immune Modulation Domain specific endpoint

[Time Frame: Day 90, censored at hospital discharge ]
Eligibility
Minimum Age: 18 Years 18 Years
Maximum Age:
Sex: All All
Gender Based:
Accepts Healthy Volunteers: NoNo
Criteria:

PLATFORM INCLUSION CRITERIA :

1. Adult patients admitted to an ICU for severe CAP within 48 hours of hospital admission with: i. symptoms or signs or both that are consistent with lower respiratory tract infection AND ii. Radiological evidence of new onset consolidation (in patients with pre-existing radiological changes, evidence of new infiltrate) 2. Requiring organ support with one or more of: i. Non-invasive ii. Invasive ventilatory support; iii. Receiving infusion of vasopressor or inotropes

PLATFORM EXCLUSION CRITERIA:

  1. Healthcare-associated pneumonia:

    i. Prior to this illness, has been an inpatient in any healthcare facility within the last 30 days ii. Resident of a nursing home or long term care facility

  2. Death is deemed to be imminent or inevitable admission within the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment
  3. Previous participation in this REMAP within the last 90 days

DOMAIN-SPECIFIC ELIGIBLE CRITERIA:

Each domain may have additional eligibility criteria. Refer to the study website for more information (www.remapcap.org).

REMAP-CAP PLATFORM INCLUSION CRITERIA:

  1. Adult patient admitted to an ICU for severe CAP within 48 hours of hospital admission with:
    1. symptoms or signs or both that are consistent with lower respiratory tract infection AND
    2. Radiological evidence of new onset consolidation (in patients with pre-existing radiological changes, evidence of new infiltrate)
  2. Up to 48 hours after ICU admission, receiving organ support with one or more of:
    1. Non-invasive or Invasive ventilatory support;
    2. Receiving infusion of vasopressor or inotropes or both

PLATFORM EXCLUSION CRITERIA:

  1. Healthcare-associated pneumonia:
    1. Prior to this illness, is known to have been an inpatient in any healthcare facility within the last 30 days
    2. Resident of a nursing home or long term care facility
  2. Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment
  3. Previous participation in this REMAP within the last 90 days

REMAP-COVID PLATFORM INCLUSION CRITERIA

1. Adult patients (≥ 18 years) hospitalised with suspected or proven COVID-19 infection. "Suspected COVID-19 infection" means the patient is clinically diagnosed based on symptoms and/or exposure and for whom a microbiology test for COVID-19 has been/will be ordered, but for whom the result is pending. "Proven COVID-19 infection" means the patient has a confirmed positive result for COVID-19 based on microbiological testing.

ADDITIONAL PLATFORM INCLUSION CRITERIA FOR ICU-BASED REMAP-COVID DOMAINS

  1. Admitted to an ICU with the following features suggestive of COVID-19-related pneumonia:
    1. symptoms or signs or both that are consistent with lower respiratory tract infection AND
    2. Radiological evidence of new onset consolidation (in patients with pre-existing radiological changes, evidence of new infiltrate)
  2. Up to 48 hours after ICU admission, receiving organ support with one or more of:
    1. Non-invasive or Invasive ventilatory support;
    2. Receiving infusion of vasopressor or inotropes or both

REMAP-COVID PLATFORM EXCLUSION CRITERIA

  1. Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment
  2. Previous participation in this REMAP within the last 90 days

DOMAIN-SPECIFIC ELIGIBLE CRITERIA:

Each domain may have additional eligibility criteria. Refer to the study website for more information (www.remapcap.org).

Contacts/Locations
Central Contact: Cameron Green
Email: info@remapcap.org
Cameron Green
Email: info@remapcap.org
Central Contact Backup: Wilma Van Bentum-Puijk, MSc
Telephone: +31 (0) 88 755 5555
Email: prepare_icu@umcutrecht.nl
Wilma Van Bentum-Puijk, MSc
Telephone: +31 (0) 88 755 5555
Email: prepare_icu@umcutrecht.nl
Study Officials: Steve Webb, Prof
Study Chair
Monash University, Study Chair REMAP-CAP Australia
Steve Webb, Prof
Study Chair
Monash University, Study Chair REMAP-CAP Australia
Colin McArthur, Dr
Study Chair
Medical Research Institute of New Zealand, Study Chair REMAP-CAP New Zealand
Colin McArthur, Dr
Study Chair
Medical Research Institute of New Zealand, Study Chair REMAP-CAP New Zealand
Marc Bonten, Prof
Study Chair
UMC Utrecht, Study Chair REMAP-CAP Europe
Marc Bonten, Prof
Study Chair
UMC Utrecht, Study Chair REMAP-CAP Europe
Lennie Derde, MD
Study Chair
UMC Utrecht, Coordinating Investigator REMAP-CAP Europe
Lennie Derde, MD
Study Chair
UMC Utrecht, Coordinating Investigator REMAP-CAP Europe
Marshall Marshall, Prof
Study Chair
Unity Health Toronto
Marshall Marshall, Prof
Study Chair
Unity Health Toronto
Angus Derek, Prof
Study Chair
University of Pittsburgh Medical Center
Locations: Australia, New South WalesAustralia, New South Wales
St Vincent's Hospital Sydney
[Not yet recruiting]
Sydney, New South Wales, Australia, 2010
St Vincent's Hospital Sydney
[Recruiting]
Sydney, New South Wales, Australia, 2010
Royal Prince Alfred Hospital
[Not yet recruiting]
Sydney, New South Wales, Australia, 2050
Royal Prince Alfred Hospital
[Not yet recruiting]
Sydney, New South Wales, Australia, 2050
Royal North Shore Hospital
[Not yet recruiting]
Sydney, New South Wales, Australia, 2065
Royal North Shore Hospital
[Recruiting]
Sydney, New South Wales, Australia, 2065
Nepean Hospital
[Not yet recruiting]
Sydney, New South Wales, Australia, 2747
Nepean Hospital
[Recruiting]
Sydney, New South Wales, Australia, 2747
Wollongong Hospital
[Not yet recruiting]
Sidney, New South Wales, Australia, 8808
Wollongong Hospital
[Recruiting]
Sydney, New South Wales, Australia, 8808
Australia, Northern TerritoryAustralia, Northern Territory
Royal Darwin Hospital,
[Not yet recruiting]
Darwin, Northern Territory, Australia, 0810
Royal Darwin Hospital,
[Not yet recruiting]
Darwin, Northern Territory, Australia, 0810
Australia, QueenslandAustralia, Queensland
Sunshine Coast University Hospital
[Not yet recruiting]
Birtinya, Queensland, Australia, 4575
Sunshine Coast University Hospital
[Not yet recruiting]
Birtinya, Queensland, Australia, 4575
Princess Alexandra Hospital
[Not yet recruiting]
Brisbane, Queensland, Australia, 4102
Princess Alexandra Hospital
[Recruiting]
Brisbane, Queensland, Australia, 4102
Logan Hospital
[Not yet recruiting]
Brisbane, Queensland, Australia, 4131
Logan Hospital
[Not yet recruiting]
Brisbane, Queensland, Australia, 4131
Toowoomba Hospital
[Not yet recruiting]
Toowoomba, Queensland, Australia, 4350
Toowoomba Hospital
[Recruiting]
Toowoomba, Queensland, Australia, 4350
Australia, South AustraliaAustralia, South Australia
The Queen Elizabeth Hospital
[Not yet recruiting]
Adelaide, South Australia, Australia, 5011
The Queen Elizabeth Hospital
[Recruiting]
Adelaide, South Australia, Australia, 5011
Australia, VictoriaAustralia, Victoria
Bendigo Hospital
[Recruiting]
Bendigo, Victoria, Australia, 3550
Bendigo Hospital
[Recruiting]
Bendigo, Victoria, Australia, 3550
University Hosptial Geelong
[Recruiting]
Geelong, Victoria, Australia, 3220
University Hosptial Geelong
[Recruiting]
Geelong, Victoria, Australia, 3220
The Alfred Hospital
[Recruiting]
Melbourne, Victoria, Australia, 3004
The Alfred Hospital
[Recruiting]
Melbourne, Victoria, Australia, 3004
Royal Melbourne Hospital
[Not yet recruiting]
Melbourne, Victoria, Australia, 3050
Royal Melbourne Hospital
[Recruiting]
Melbourne, Victoria, Australia, 3050
St Vincent's Hospital Melbourne
[Not yet recruiting]
Melbourne, Victoria, Australia, 3065
St Vincent's Hospital Melbourne
[Recruiting]
Melbourne, Victoria, Australia, 3065
Australia, Western AustraliaAustralia, Western Australia
Royal Perth Hospital
[Not yet recruiting]
Perth, Western Australia, Australia, 6000
Royal Perth Hospital
[Recruiting]
Perth, Western Australia, Australia, 6000
Sir Charles Gairdner Hospital
[Not yet recruiting]
Perth, Western Australia, Australia, 6009
Sir Charles Gairdner Hospital
[Recruiting]
Perth, Western Australia, Australia, 6009
St John of God Hospital Midland
[Not yet recruiting]
Perth, Western Australia, Australia, 6056
St John of God Hospital Midland
[Recruiting]
Perth, Western Australia, Australia, 6056
Fiona Stanley Hospital
[Not yet recruiting]
Perth, Western Australia, Australia, 6150
Fiona Stanley Hospital
[Recruiting]
Perth, Western Australia, Australia, 6150
St John of God Hospital Murdoch
[Not yet recruiting]
Perth, Western Australia, Australia, 6150
St John of God Hospital Murdoch
[Not yet recruiting]
Perth, Western Australia, Australia, 6150
BelgiumBelgium
AZ Sint-Jan
[Not yet recruiting]
Brugge, Belgium, 8000
Contact: Marc Bourgeois, MD
AZ Sint-Jan
[Not yet recruiting]
Brugge, Belgium, 8000
Contact: Marc Bourgeois, MD
CHU de Charleroi - Hôpital Civil Marie Curie
[Not yet recruiting]
Charleroi, Belgium, 6042
Contact: Patrick Biston, MD
CHU de Charleroi - Hôpital Civil Marie Curie
[Not yet recruiting]
Charleroi, Belgium, 6042
Contact: Patrick Biston, MD
Universitair Ziekenhuis Antwerp
[Not yet recruiting]
Edegem, Belgium, 2650
Contact: Philippe Jorens, Prof.
Universitair Ziekenhuis Antwerp
[Not yet recruiting]
Edegem, Belgium, 2650
Contact: Philippe Jorens, Prof.
Universitair Ziekenhuis Gent
[Recruiting]
Gent, Belgium, 9000
Contact: Pieter Depuydt, Prof. Pieter.Depuydt@UGent.be
Universitair Ziekenhuis Gent
[Recruiting]
Gent, Belgium, 9000
Contact: Pieter Depuydt, Prof. Pieter.Depuydt@UGent.be
CanadaCanada
St. Joseph's Healthcare Hamilton
[Recruiting]
Hamilton, Canada
Contact: Deborah Cook, MD
St. Joseph's Healthcare Hamilton
[Recruiting]
Hamilton, Canada
Contact: Deborah Cook, MD
Centre Hospitalier de l'Université de Sherbrooke
[Recruiting]
Sherbrooke, Canada
Contact: Francois Lamontagne, MD
Centre Hospitalier de l'Université de Sherbrooke
[Recruiting]
Sherbrooke, Canada
Contact: Francois Lamontagne, MD
St. Michael's Hospital Unity Health Toronto
[Recruiting]
Toronto, Canada
Contact: John Marshall, MD
St. Michael's Hospital Unity Health Toronto
[Recruiting]
Toronto, Canada
Contact: John Marshall, MD
CroatiaCroatia
General County Hospital Požega
[Recruiting]
Požega, Croatia, 34000
Contact: Zdravko Andrić, MD
General County Hospital Požega
[Recruiting]
Požega, Croatia, 34000
Contact: Zdravko Andrić, MD
University Hospital Centre Zagreb
[Recruiting]
Zagreb, Croatia, 10000
Contact: Ana Vujaklija Brajković, MD
University Hospital Centre Zagreb
[Recruiting]
Zagreb, Croatia, 10000
Contact: Ana Vujaklija Brajković, MD
University Hospital for Infectious Diseases
[Recruiting]
Zagreb, Croatia, 10000
Contact: Bruno Barsić, MD
University Hospital for Infectious Diseases
[Recruiting]
Zagreb, Croatia, 10000
Contact: Bruno Barsić, MD
GermanyGermany
Charité - Universitätsmedizin Berlin - Infektiologie und Pneumologie
[Not yet recruiting]
Berlin, Germany, 10117
Contact: Martin Witzenrath, Prof. Dr.
Charité - Universitätsmedizin Berlin - Infektiologie und Pneumologie
[Not yet recruiting]
Berlin, Germany, 10117
Contact: Martin Witzenrath, Prof. Dr.
Charité - Universitätsmedizin Berlin - Nephrologie
[Not yet recruiting]
Berlin, Germany, 10117
Contact: André Finn, MD
Charité - Universitätsmedizin Berlin - Nephrologie
[Not yet recruiting]
Berlin, Germany, 10117
Contact: André Finn, MD
Vivantes Klinikum Neukölln
[Not yet recruiting]
Berlin, Germany, 12351
Contact: Lorenz Reill, MD
Vivantes Klinikum Neukölln
[Not yet recruiting]
Berlin, Germany, 12351
Contact: Lorenz Reill, MD
Universitätsklinikum Köln
[Not yet recruiting]
Cologne, Germany, 50937
Contact: Lars Pester
Universitätsklinikum Köln
[Not yet recruiting]
Cologne, Germany, 50937
Contact: Lars Pester
Universitätsklinikum Frankfurt
[Not yet recruiting]
Frankfurt, Germany, 60590
Contact: Gernot Rohde, Prof. Dr.
Universitätsklinikum Frankfurt
[Not yet recruiting]
Frankfurt, Germany, 60590
Contact: Gernot Rohde, Prof. Dr.
University Medical Center Hamburg-Eppendorf (UKE)
[Not yet recruiting]
Hamburg, Germany, 20251
Contact: Stefan Klug, Prof. Dr.
University Medical Center Hamburg-Eppendorf (UKE)
[Not yet recruiting]
Hamburg, Germany, 20251
Contact: Stefan Klug, Prof. Dr.
Medizinische Hochschule Hannover
[Not yet recruiting]
Hannover, Germany, 30625
Contact: Sascha David, MD
Medizinische Hochschule Hannover
[Not yet recruiting]
Hannover, Germany, 30625
Contact: Sascha David, MD
Universitätsklinikum Jena
[Recruiting]
Jena, Germany, 07747
Contact: Mathias W. Pletz, Prof. Dr. mathias.pletz@med.uni-jena.de
Universitätsklinikum Jena
[Recruiting]
Jena, Germany, 07747
Contact: Mathias W. Pletz, Prof. Dr. mathias.pletz@med.uni-jena.de
Universitätsklinikum Leipzig
[Recruiting]
Leipzig, Germany, 04103
Contact: Sirak Petros, Prof. Dr. Sirak.Petros@uniklinik-leipzig.de
Universitätsklinikum Leipzig
[Recruiting]
Leipzig, Germany, 04103
Contact: Sirak Petros, Prof. Dr. Sirak.Petros@uniklinik-leipzig.de
Universitäts Klinikum Tübingen
[Not yet recruiting]
Tübingen, Germany, 72076
Contact: Siri Göpel, MD
Universitäts Klinikum Tübingen
[Not yet recruiting]
Tübingen, Germany, 72076
Contact: Siri Göpel, MD
Universitätsklinikum Würzburg
[Not yet recruiting]
Würzburg, Germany, 97080
Contact: Dirk Weismann, MD
Universitätsklinikum Würzburg
[Not yet recruiting]
Würzburg, Germany, 97080
Contact: Dirk Weismann, MD
HungaryHungary
Jósa András County Hospital
[Recruiting]
Nyíregyháza, Hungary, 4400
Contact: Gábor Szigligeti, MD
Jósa András County Hospital
[Recruiting]
Nyíregyháza, Hungary, 4400
Contact: Gábor Szigligeti, MD
Csolnoky Ferenc Kórház - Veszprem County Hospital
[Not yet recruiting]
Veszprém, Hungary, 8200
Contact: Béla Gál, MD
Csolnoky Ferenc Kórház - Veszprem County Hospital
[Not yet recruiting]
Veszprém, Hungary, 8200
Contact: Béla Gál, MD
Almási Balogh Pál Kórház
[Recruiting]
Ózd, Hungary, 3600
Contact: János Bélteczki, MD
Almási Balogh Pál Kórház
[Recruiting]
Ózd, Hungary, 3600
Contact: János Bélteczki, MD
IrelandIreland
Beaumont Hospital
[Not yet recruiting]
Dublin, Ireland
Contact: Ger Curley, Prof.
Beaumont Hospital
[Not yet recruiting]
Dublin, Ireland
Contact: Ger Curley, Prof.
St. Vincent's University Hospital
[Recruiting]
Dublin, Ireland
Contact: Alistair Nichol, Prof.
Contact: alistair.nichol@ucd.ie
St. Vincent's University Hospital
[Recruiting]
Dublin, Ireland
Contact: Alistair Nichol, Prof.
Contact: alistair.nichol@ucd.ie
University Hospital Galway
[Recruiting]
Galway, Ireland
Contact: John Laffey, M.D.
University Hospital Galway
[Recruiting]
Galway, Ireland
Contact: John Laffey, M.D.
NetherlandsNetherlands
Meander Medisch Centrum
[Recruiting]
Amersfoort, Netherlands
Contact: Laura van Gulik, M.D.
Meander Medisch Centrum
[Recruiting]
Amersfoort, Netherlands
Contact: Laura van Gulik, M.D.
Jeroen Bosch Ziekenhuis
[Recruiting]
Den Bosch, Netherlands
Contact: Koen Simons, M.D.
Jeroen Bosch Ziekenhuis
[Recruiting]
Den Bosch, Netherlands
Contact: Koen Simons, M.D.
Martini Hospital Groningen
[Withdrawn]
Groningen, Netherlands
Martini Hospital Groningen
[Withdrawn]
Groningen, Netherlands
University Medical Center Groningen
[Withdrawn]
Groningen, Netherlands
University Medical Center Groningen
[Withdrawn]
Groningen, Netherlands
Leiden University Medical Center
[Recruiting]
Leiden, Netherlands
Contact: Evert De Jonge, Prof.
Contact: e.de_jonge@lumc.nl
Leiden University Medical Center
[Recruiting]
Leiden, Netherlands
Contact: Evert De Jonge, Prof.
Contact: e.de_jonge@lumc.nl
Canisius Wilhelmina Ziekenhuis
[Recruiting]
Nijmegen, Netherlands
Contact: Oscar Hoiting, M.D.
Contact: O.Hoiting@cwz.nl
Canisius Wilhelmina Ziekenhuis
[Recruiting]
Nijmegen, Netherlands
Contact: Oscar Hoiting, M.D.
Contact: O.Hoiting@cwz.nl
Radboud University Medical Center
[Not yet recruiting]
Nijmegen, Netherlands
Contact: Jeroen Schouten, M.D.
Radboud University Medical Center
[Not yet recruiting]
Nijmegen, Netherlands
Contact: Jeroen Schouten, M.D.
University Medical Center Utrecht
[Recruiting]
Utrecht, Netherlands, 3584 CX
Contact: Marc Bonten, Prof. +31 88 75 573 94 M.J.M.Bonten@umcutrecht.nl
Contact: Lennie Derde, MD +31 (0)88 755 5555 L.P.G.Derde@umcutrecht.nl
University Medical Center Utrecht
[Recruiting]
Utrecht, Netherlands, 3584 CX
Contact: Marc Bonten, Prof. +31 88 75 573 94 M.J.M.Bonten@umcutrecht.nl
Contact: Lennie Derde, MD +31 (0)88 755 5555 L.P.G.Derde@umcutrecht.nl
New ZealandNew Zealand
North Shore Hospital
[Recruiting]
Auckland, New Zealand, 0620
Contact: Robert Everitt, MD
North Shore Hospital
[Recruiting]
Auckland, New Zealand, 0620
Contact: Robert Everitt, MD
CVICU, Auckland City Hospital
[Recruiting]
Auckland, New Zealand, 1023
Contact: Shay McGuinness, MD
CVICU, Auckland City Hospital
[Recruiting]
Auckland, New Zealand, 1023
Contact: Shay McGuinness, MD
DCCM, Auckland City Hospital
[Recruiting]
Auckland, New Zealand, 1023
Contact: Colin McArthur, MD
DCCM, Auckland City Hospital
[Recruiting]
Auckland, New Zealand, 1023
Contact: Colin McArthur, MD
Middlemore Hospital
[Recruiting]
Auckland, New Zealand, 2104
Contact: Tony Williams, MD
Middlemore Hospital
[Recruiting]
Auckland, New Zealand, 2104
Contact: Tony Williams, MD
Christchurch Hospital
[Recruiting]
Christchurch, New Zealand, 4710
Contact: Seton Henderson, MD
Christchurch Hospital
[Recruiting]
Christchurch, New Zealand, 4710
Contact: Seton Henderson, MD
Waikato Hospital
[Recruiting]
Hamilton, New Zealand, 3204
Contact: Robert Martynoga, MD
Waikato Hospital
[Recruiting]
Hamilton, New Zealand, 3204
Contact: Robert Martynoga, MD
Rotorua Hospital
[Recruiting]
Rotorua, New Zealand, 3010
Contact: Ulrike Buehner, MD
Rotorua Hospital
[Recruiting]
Rotorua, New Zealand, 3010
Contact: Ulrike Buehner, MD
Tauranga Hospital
[Recruiting]
Tauranga, New Zealand, 3112
Contact: Troy Browne, MD
Tauranga Hospital
[Recruiting]
Tauranga, New Zealand, 3112
Contact: Troy Browne, MD
Wellington Regional Hospital
[Recruiting]
Wellington, New Zealand, 6021
Contact: Paul Young, MD
Wellington Regional Hospital
[Recruiting]
Wellington, New Zealand, 6021
Contact: Paul Young, MD
Whangarei Hospital
[Recruiting]
Whangarei, New Zealand, 0148
Contact: Katherine Perry, MD
Whangarei Hospital
[Recruiting]
Whangarei, New Zealand, 0148
Contact: Katherine Perry, MD
PortugalPortugal
Centro Hospitalar do Medio Tejo
[Recruiting]
Abrantes, Portugal
Contact: Nuno Catorze, M.D.
Contact: nunocatorze@gmail.com
Centro Hospitalar do Medio Tejo
[Recruiting]
Abrantes, Portugal
Contact: Nuno Catorze, M.D.
Contact: nunocatorze@gmail.com
Hospital Lusíadas Lisbon
[Not yet recruiting]
Lisboa, Portugal
Contact: Nunes Nunes, M.D.
Hospital Lusíadas Lisbon
[Not yet recruiting]
Lisboa, Portugal
Contact: Nunes Nunes, M.D.
RomaniaRomania
Clinical Hospital of Infectious and Tropical Diseases "Dr. Victor Babes"
[Recruiting]
Bucharest, Romania, 030303
Contact: Simin-Aysel Florescu, MD
Clinical Hospital of Infectious and Tropical Diseases "Dr. Victor Babes"
[Recruiting]
Bucharest, Romania, 030303
Contact: Simin-Aysel Florescu, MD
SpainSpain
Institut Hospital del Mar d'Investigacions Mèdiques
[Not yet recruiting]
Barcelona, Spain
Contact: Rosana Munoz, M.D.
Institut Hospital del Mar d'Investigacions Mèdiques
[Not yet recruiting]
Barcelona, Spain
Contact: Rosana Munoz, M.D.
Hospital Universitario Reina Sofia
[Recruiting]
Córdoba, Spain
Contact: Rafael Leon-Lopez, M.D.
Contact: rafael.leon.lop@hotmail.com
Hospital Universitario Reina Sofia
[Recruiting]
Córdoba, Spain
Contact: Rafael Leon-Lopez, M.D.
Contact: rafael.leon.lop@hotmail.com
United KingdomUnited Kingdom
Basingstoke and North Hampshire Hospital
[Not yet recruiting]
Basingstoke, United Kingdom
Contact: Antony Ashton, MD
Basingstoke and North Hampshire Hospital
[Not yet recruiting]
Basingstoke, United Kingdom
Contact: Antony Ashton, MD
Southmead Hospital
[Not yet recruiting]
Bristol, United Kingdom
Contact: Matt Thomas, MD
Southmead Hospital
[Not yet recruiting]
Bristol, United Kingdom
Contact: Matt Thomas, MD
University Hospital Coventry
[Recruiting]
Coventry, United Kingdom
Contact: Christopher Bassford, MD christopher.bassford@uhcw.nhs.uk
University Hospital Coventry
[Recruiting]
Coventry, United Kingdom
Contact: Christopher Bassford, MD christopher.bassford@uhcw.nhs.uk
Darlington Memorial Hospital
[Recruiting]
Darlington, United Kingdom
Contact: James Limb, MD j.limb@nhs.net
Darlington Memorial Hospital
[Recruiting]
Darlington, United Kingdom
Contact: James Limb, MD j.limb@nhs.net
University Hospital of North Durham
[Recruiting]
Durham, United Kingdom
Contact: James Limb, MD j.limb@nhs.net
University Hospital of North Durham
[Recruiting]
Durham, United Kingdom
Contact: James Limb, MD j.limb@nhs.net
Leeds Teaching Hospitals NHS Trust
[Recruiting]
Leeds, United Kingdom
Contact: Elankumaran Paramasivam, MD eparamasivam@nhs.net
Leeds Teaching Hospitals NHS Trust
[Recruiting]
Leeds, United Kingdom
Contact: Elankumaran Paramasivam, MD eparamasivam@nhs.net
Maidstone Hospital - Maidstone and Tunbridge Wells NHS Trust
[Recruiting]
Maidstone, United Kingdom
Contact: David Golden, MD david.golden@nhs.net
Maidstone Hospital - Maidstone and Tunbridge Wells NHS Trust
[Recruiting]
Maidstone, United Kingdom
Contact: David Golden, MD david.golden@nhs.net
The James Cook University Hospital
[Recruiting]
Middlesbrough, United Kingdom
Contact: Jeremy Henning, MD jeremy.henning@nhs.net
The James Cook University Hospital
[Recruiting]
Middlesbrough, United Kingdom
Contact: Jeremy Henning, MD jeremy.henning@nhs.net
Milton Keynes University Hospital
[Not yet recruiting]
Milton Keynes, United Kingdom
Contact: Richard Stewart, MD
Milton Keynes University Hospital
[Not yet recruiting]
Milton Keynes, United Kingdom
Contact: Richard Stewart, MD
Northampton General Hospital
[Not yet recruiting]
Northampton, United Kingdom
Contact: Jonathan Wilkinson, MD
Northampton General Hospital
[Not yet recruiting]
Northampton, United Kingdom
Contact: Jonathan Wilkinson, MD
Queen's Medical Centre - Nottingham University Hospitals NHS Trust
[Recruiting]
Nottingham, United Kingdom
Contact: Daniel Harvey, MD Daniel.harvey@nuh.nhs.uk
Queen's Medical Centre - Nottingham University Hospitals NHS Trust
[Recruiting]
Nottingham, United Kingdom
Contact: Daniel Harvey, MD Daniel.harvey@nuh.nhs.uk
Poole Hospital NHS Foundation Trust
[Recruiting]
Poole, United Kingdom
Contact: Henrik Reschreiter, MD henrik.reschreiter@poole.nhs.uk
Poole Hospital NHS Foundation Trust
[Recruiting]
Poole, United Kingdom
Contact: Henrik Reschreiter, MD henrik.reschreiter@poole.nhs.uk
Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust
[Recruiting]
Portsmouth, United Kingdom
Contact: David Pogson, MD david.pogson@porthosp.nhs.uk
Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust
[Recruiting]
Portsmouth, United Kingdom
Contact: David Pogson, MD david.pogson@porthosp.nhs.uk
Royal Berkshire Hospital
[Not yet recruiting]
Reading, United Kingdom
Contact: Andrew Walden, MD
Royal Berkshire Hospital
[Not yet recruiting]
Reading, United Kingdom
Contact: Andrew Walden, MD
University Hospital of North Tees
[Recruiting]
Stockton-on-Tees, United Kingdom
Contact: Farooq Brohi, MD farooq.brohi@nth.nhs.uk
University Hospital of North Tees
[Recruiting]
Stockton-on-Tees, United Kingdom
Contact: Farooq Brohi, MD farooq.brohi@nth.nhs.uk
Royal Cornwall Hospital
[Recruiting]
Truro, United Kingdom
Contact: Michael Spivey, MD michaelspivey@nhs.net
Royal Cornwall Hospital
[Recruiting]
Truro, United Kingdom
Contact: Michael Spivey, MD michaelspivey@nhs.net
Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust
[Recruiting]
Tunbridge Wells, United Kingdom
Contact: David Golden, MD david.golden@nhs.net
Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust
[Recruiting]
Tunbridge Wells, United Kingdom
Contact: David Golden, MD david.golden@nhs.net
York Hospital
[Not yet recruiting]
York, United Kingdom
Contact: Joseph Carter, MD
York Hospital
[Not yet recruiting]
York, United Kingdom
Contact: Joseph Carter, MD
IPDSharing
Plan to Share IPD: Yes Yes
Supporting Information:
Supporting Information:
Time Frame:
Time Frame:
Access Criteria:
Access Criteria:
URL: URL:
References
Citations:
Links:
Description: PREPARE website
Description: PREPARE website
Description: REMAP-CAP Study Website
Description: REMAP-CAP Study Website
Description: CAPTIC Website
Description: CAPTIC Website
Description: Protocol publication
Available IPD/Information:

Scroll up to access the controls Scroll to the Study top

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services